$RGLS
Regulus Therapeutics Inc.

2015 Q4 Form 10-Q Financial Statement

#000162828015008379 Filed on November 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $10.86M $1.865M $1.083M
YoY Change 157.41% 72.21% -82.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.430M $4.250M $2.570M
YoY Change 65.55% 65.37% 33.85%
% of Gross Profit
Research & Development $12.79M $10.97M $10.17M
YoY Change 22.16% 7.79% 43.16%
% of Gross Profit
Depreciation & Amortization $410.0K $380.0K $400.0K
YoY Change 5.13% -5.0% 8.11%
% of Gross Profit
Operating Expenses $18.22M $15.21M $12.74M
YoY Change 32.5% 19.37% 41.22%
Operating Profit -$13.35M -$11.66M
YoY Change 14.46% 301.34%
Interest Expense $140.0K $6.000K $10.00K
YoY Change 40.0% -40.0% 42.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.220M -$13.02M -$9.798M
YoY Change -67.43% 32.84% 351.73%
Income Tax $0.00 -$16.00K $0.00
% Of Pretax Income
Net Earnings -$7.226M -$13.00M -$9.798M
YoY Change -67.4% 32.68% 352.77%
Net Earnings / Revenue -66.54% -697.05% -904.71%
Basic Earnings Per Share -$0.14 -$0.25 -$0.23
Diluted Earnings Per Share -$1.654M -$0.25 -$0.26
COMMON SHARES
Basic Shares Outstanding 52.34M shares 51.99M shares 43.41M shares
Diluted Shares Outstanding 51.99M shares 44.86M shares

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.1M $130.3M $94.10M
YoY Change -28.55% 38.47% -24.05%
Cash & Equivalents $15.96M $18.32M $9.958M
Short-Term Investments $98.10M $112.0M $84.10M
Other Short-Term Assets $759.0K $6.200M $4.000M
YoY Change 2.29% 55.0% 207.69%
Inventory
Prepaid Expenses $5.500M
Receivables $10.00M $300.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $134.3M $136.8M $98.02M
YoY Change -18.61% 39.57% -21.76%
LONG-TERM ASSETS
Property, Plant & Equipment $5.400M $3.488M $3.840M
YoY Change 51.35% -9.17% -3.54%
Goodwill
YoY Change
Intangibles $1.081M $1.072M $1.114M
YoY Change -6.0% -3.77% -2.71%
Long-Term Investments
YoY Change
Other Assets $344.0K $2.077M $1.038M
YoY Change -81.0% 100.1% 483.15%
Total Long-Term Assets $6.825M $6.637M $5.992M
YoY Change 4.53% 10.76% 12.97%
TOTAL ASSETS
Total Short-Term Assets $134.3M $136.8M $98.02M
Total Long-Term Assets $6.825M $6.637M $5.992M
Total Assets $141.1M $143.4M $104.0M
YoY Change -17.73% 37.91% -20.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.717M $3.392M $2.642M
YoY Change 24.18% 28.39% 131.75%
Accrued Expenses $6.329M $7.409M $3.633M
YoY Change 43.78% 103.94% 113.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $12.63M $14.81M $11.89M
YoY Change -64.11% 24.52% -12.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $10.70M
YoY Change -100.0% -23.02%
Other Long-Term Liabilities $0.00 $693.0K $1.142M
YoY Change -100.0% -39.32% -26.7%
Total Long-Term Liabilities $0.00 $693.0K $1.142M
YoY Change -100.0% -39.32% -26.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.63M $14.81M $11.89M
Total Long-Term Liabilities $0.00 $693.0K $1.142M
Total Liabilities $17.01M $17.59M $29.94M
YoY Change -56.91% -41.26% -17.18%
SHAREHOLDERS EQUITY
Retained Earnings -$191.5M -$184.3M -$113.6M
YoY Change 41.06% 62.23% 47.23%
Common Stock $315.7M $310.3M $43.00K
YoY Change 17.82% 721493.02% 2.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $124.1M $125.9M $74.08M
YoY Change
Total Liabilities & Shareholders Equity $141.1M $143.4M $104.0M
YoY Change -17.73% 37.91% -20.35%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$7.226M -$13.00M -$9.798M
YoY Change -67.4% 32.68% 352.77%
Depreciation, Depletion And Amortization $410.0K $380.0K $400.0K
YoY Change 5.13% -5.0% 8.11%
Cash From Operating Activities -$17.04M -$11.80M -$8.800M
YoY Change 46.14% 34.09% 98.65%
INVESTING ACTIVITIES
Capital Expenditures -$490.0K -$460.0K -$390.0K
YoY Change 1533.33% 17.95% 14.71%
Acquisitions
YoY Change
Other Investing Activities $13.53M $5.960M $8.960M
YoY Change -134.86% -33.48% -132.99%
Cash From Investing Activities $13.05M $5.490M $8.580M
YoY Change -133.6% -36.01% -131.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.640M 3.540M 160.0K
YoY Change -97.89% 2112.5% -99.65%
NET CHANGE
Cash From Operating Activities -17.04M -11.80M -8.800M
Cash From Investing Activities 13.05M 5.490M 8.580M
Cash From Financing Activities 1.640M 3.540M 160.0K
Net Change In Cash -2.350M -2.770M -60.00K
YoY Change -108.59% 4516.67% -100.42%
FREE CASH FLOW
Cash From Operating Activities -$17.04M -$11.80M -$8.800M
Capital Expenditures -$490.0K -$460.0K -$390.0K
Free Cash Flow -$16.55M -$11.34M -$8.410M
YoY Change 42.3% 34.84% 105.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-134000 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
267929000 USD
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
310233000 USD
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1627000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4710000 USD
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2634000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11607000 USD
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1949096 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3762394 shares
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2188000 USD
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3392000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1235000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1130000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4402000 USD
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7409000 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-197000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001505512
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52342653 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
dei Trading Symbol
TradingSymbol
RGLS
CY2014Q4 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
122580000 USD
CY2015Q3 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
112070000 USD
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
274000 USD
CY2015Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
325000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2499389 shares
us-gaap Interest Expense
InterestExpense
22000 USD
us-gaap Interest Paid
InterestPaid
30000 USD
us-gaap Interest Paid
InterestPaid
22000 USD
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2269605 shares
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
106000 USD
CY2014Q4 us-gaap Assets
Assets
171480000 USD
CY2015Q3 us-gaap Assets
Assets
143447000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
164951000 USD
CY2015Q3 us-gaap Assets Current
AssetsCurrent
136810000 USD
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
159488000 USD
CY2015Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
128832000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
179000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17807000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9958000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37327000 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18324000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7849000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19003000 USD
CY2015Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9219631 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48944530 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52342653 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48944530 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52342653 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
49000 USD
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9822000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34562000 USD
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12960000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48426000 USD
CY2014Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
23400000 USD
CY2014Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
23397000 USD
CY2015Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2015Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1356738 shares
CY2015Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2015-10-09
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3097000 USD
CY2015Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2009000 USD
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3252000 USD
CY2015Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2083000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1098000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1177000 USD
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
115000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-50000 USD
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2108000 USD
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1999000 USD
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0010
CY2014 us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
1.10
CY2014 us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.097
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-18000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-73000 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2569000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8255000 USD
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4245000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13703000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9798000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34511000 USD
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13016000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48544000 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000 USD
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-22000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
50000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1470000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1024000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
610000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1649000 USD
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-203000 USD
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-257000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-980000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2257000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
147000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-109000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
882000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
91000 USD
CY2014Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1449212 shares
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1150000 USD
CY2015Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1072000 USD
CY2014Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
86000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
283000 USD
CY2015Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
335000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
686000 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
10000 USD
CY2014Q4 us-gaap Liabilities
Liabilities
39466000 USD
us-gaap Interest Expense
InterestExpense
31000 USD
CY2015Q3 us-gaap Interest Expense
InterestExpense
6000 USD
CY2015Q3 us-gaap Liabilities
Liabilities
17585000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
171480000 USD
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143447000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35192000 USD
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14809000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10371000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5378000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
9633000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8434000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-27853000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-32815000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-9798000 USD
us-gaap Net Income Loss
NetIncomeLoss
-34512000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-13000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-48522000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11583000 USD
CY2014Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
1785000 USD
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
614000 USD
CY2015Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
0 USD
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-1811000 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
12742000 USD
us-gaap Operating Expenses
OperatingExpenses
38827000 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
15210000 USD
us-gaap Operating Expenses
OperatingExpenses
57296000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11659000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-35377000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13345000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-47397000 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1811000 USD
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2077000 USD
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000 USD
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
96000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1022000 USD
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
693000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
53000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
40000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1120000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
873000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
52268000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
67064000 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4934000 USD
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4759000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9853000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
492000 USD
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
0 USD
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
1400000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
63074000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
76411000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
624000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5001000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3568000 USD
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3488000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10173000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30572000 USD
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10965000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43593000 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0 USD
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1400000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135767000 USD
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184289000 USD
CY2014Q3 us-gaap Revenues
Revenues
1083000 USD
us-gaap Revenues
Revenues
3450000 USD
CY2015Q3 us-gaap Revenues
Revenues
1865000 USD
us-gaap Revenues
Revenues
9899000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4710000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11607000 USD
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2177821 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
653000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1776000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6643000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5781674 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.95
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.27
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.58
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.23
CY2015Q1 us-gaap Share Price
SharePrice
18.58
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
122416000 USD
CY2015Q3 us-gaap Short Term Investments
ShortTermInvestments
112002000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1984000 shares
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
132014000 USD
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
125862000 USD
CY2014 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
3000 USD
us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
13000 USD
CY2014 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
167000 USD
us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
81000 USD
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44855463 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43155601 shares
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51990460 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51052068 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43406251 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43155601 shares
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51990460 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51052068 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001628280-15-008379-index-headers.html Edgar Link pending
0001628280-15-008379-index.html Edgar Link pending
0001628280-15-008379.txt Edgar Link pending
0001628280-15-008379-xbrl.zip Edgar Link pending
ex-311xcertificationofprin.htm Edgar Link pending
ex-312xcertificationofprin.htm Edgar Link pending
ex-321xcertificationpursua.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20150930.xml Edgar Link completed
rgls-20150930.xsd Edgar Link pending
rgls-20150930_cal.xml Edgar Link unprocessable
rgls-20150930_def.xml Edgar Link unprocessable
rgls-20150930_lab.xml Edgar Link unprocessable
rgls-20150930_pre.xml Edgar Link unprocessable
rgls20150930-10q.htm Edgar Link pending
Show.js Edgar Link pending